Fintel reports that on February 13, 2025, Scotiabank initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a Sector ...

We recently published an article titled These 10 Companies Led Monday’s Downturn. In this article, we are going to take a ...

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

The excitement surrounding Viking Therapeutics (NASDAQ: VKTX) stock has been dying down significantly lately. Many investors ...

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price target ...

We recently published a list of 15 Stocks That Took a Nosedive in January. In this article, we are going to take a look at ...

As previously reported, Scotiabank analyst George Farmer initiated coverage of Viking Therapeutics (VKTX) with an Outperform rating and $102 ...

Viking Therapeutics VKTX has outperformed the market over the past 5 years by 22.07% on an annualized basis producing an ...

Viking Therapeutics announces its fourth-quarter financial results after Wednesday's closing bell. Here's a look at the ...

We recently published a list of Jim Cramer’s Thoughts on These 7 Stocks. In this article, we are going to take a look at ...

Shares of Viking Therapeutics have fallen by more than half since the stock peaked early last year. Viking Therapeutics is developing a drug that might be able to outperform today's most popular ...

CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which demonstrated up to 14.7% ...